Biological roles and potential clinical value of tRNA-derived small RNAs in gastrointestinal malignancies.
Yongfu Shao, Xuan Yu, Weihong Zhou...
https://pubmed.ncbi.nlm.nih.gov/41069160Actively Recruiting
Age: 18Years +
All Genders
Healthy Volunteers
ID07265271
Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)
Led by City of Hope Medical Center · Updated on 2026-06-05
600
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatocellular carcinoma (HCC) is a common and serious form of liver cancer, often diagnosed at an advanced stage which leads to poor survival rates. Early detection is crucial as early-stage HCC can have significantly better outcomes with curative treatments. This study focuses on developing a new multi-omics liquid biopsy test that analyzes various types of non-coding RNAs to improve accurate early detection of HCC, especially in patients with different liver disease backgrounds. The study involves collecting blood and other biological samples from three groups: patients diagnosed with HCC, patients with chronic liver disease but no HCC, and healthy individuals without liver disease or cancer. Researchers will perform comprehensive small RNA sequencing and PCR-based tests to identify and validate biomarkers that distinguish early-stage HCC from other liver conditions. Advanced machine learning techniques will be used to build a diagnostic classifier based on circulating small RNAs. Participants will provide biospecimens and clinical data while undergoing standard diagnostic and staging procedures. The research team will assess the diagnostic performance of the multi-omics biomarker panel at baseline and validate the model in independent patient groups. They will also explore specific biomarker profiles related to different causes of HCC. Overall, this study aims to improve non-invasive early detection methods for HCC to guide timely and effective treatment decisions.
CONDITIONS
Brief Title
Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 100 years
- Histologically confirmed hepatocellular carcinoma diagnosis
- Clinical diagnosis of chronic liver disease, including chronic hepatitis or liver cirrhosis, without hepatocellular carcinoma
- Healthy volunteers without known liver disease or malignancy
- Received standard diagnostic and staging procedures as per local guidelines
- Availability of blood or other biospecimens
- Ability to provide written informed consent
You will not qualify if you...
- Unable or unwilling to provide informed consent
- History of other active cancers within the past 5 years
- Previous liver transplantation
- Severe systemic infection or inflammatory disease at enrollment
- Inadequate quality or quantity of samples
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Baseline
Participants provide blood or other biospecimens for multi-omics profiling to identify biomarkers distinguishing hepatocellular carcinoma, chronic liver disease, and healthy controls.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
City of Hope Medical Center
Duarte, California, United States, 91016
Actively Recruiting
Loading map...
Research Team
G
Goel Ajay, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Role of tRNA-derived small RNAs(tsRNAs) in the diagnosis and treatment of malignant tumours.
Mingwen Mao, Weina Chen, Xingbiao Huang...
https://pubmed.ncbi.nlm.nih.gov/37480078Emerging roles of tRNA-derived small RNAs in cancer biology.
Saebyeol Lee, Jungeun Kim, Paul N Valdmanis...
https://pubmed.ncbi.nlm.nih.gov/37430089tRNA-derived small RNAs in human cancers: roles, mechanisms, and clinical application.
Manli Zhou, Xiaoyun He, Jing Zhang...
https://pubmed.ncbi.nlm.nih.gov/386226945'-transfer RNA halve-lysine-CTT as a promising biomarker for early detection of hepatocellular carcinoma.
Jie Yuan, Wen-Chao Gu, Tian-Xin Xu...
https://pubmed.ncbi.nlm.nih.gov/41281472Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma.
Chloé Sauzay, Alexandra Petit, Anne-Marie Bourgeois...
https://pubmed.ncbi.nlm.nih.gov/27732875Hepatocellular carcinoma.
Josep M Llovet, Robin Kate Kelley, Augusto Villanueva...
https://pubmed.ncbi.nlm.nih.gov/33479224Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis.
Hao Xing, Yi-Jie Zheng, Jun Han...
https://pubmed.ncbi.nlm.nih.gov/30257796Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Jong Young Choi, Seung Won Jung, Hee Yeon Kim...
https://pubmed.ncbi.nlm.nih.gov/23372355Evaluation of serum hsa_tsr014055 as a potential biomarker for diagnosis and prognosis of hepatocellular carcinoma.
Jing Xu, Bairong Chen, Jing Qi...
https://pubmed.ncbi.nlm.nih.gov/40618217